Is there any generic version of Gilteritinib and its market price comparison?

Gilteritinib (Gilteritinib) is a targeted drug mainly used to treat relapsed or refractory acute myeloid leukemia (AML). The drug has been approved for marketing in China, but because it has not yet been included in the medical insurance system, its clinical accessibility is still limited. Patients may encounter certain difficulties if they wish to purchase drugs directly from domestic hospital pharmacies, which forces some patients to seek overseas drug purchase channels to meet their treatment needs.

In foreign markets, the original drug of gilitinib is developed and produced by Astellas (Astellas) pharmaceutical company. The currently available versions mainly include the European version and the Hong Kong version. Among them, the price of the Hong Kong version of giritinib is extremely high, and the price of each box of the drug can reach 100,000 yuan, which brings a heavy financial burden to the patient's family. Although the price of the European version is slightly lower, it is still expensive overall. Therefore, the high cost of drugs has become the biggest problem for many patients with long-term medication.

In order to meet the needs of more patients, some countries have approved the marketing of generic drugs of giritinib. The price of generic drug versions represented by Laos is only between one thousand and two thousand yuan, which is much lower than the original drug. This price advantage significantly reduces the economic pressure of treatment on patients, and is especially feasible for leukemia patients who require long-term medication. It is worth noting that the generic drug of giritinib is basically the same as the original drug in terms of drug ingredients and mechanism of action, and can achieve similar therapeutic effects.

Generally speaking, although giritinib has entered the domestic market, medical insurance coverage has not yet been implemented, and the problem of high price is still prominent. For patients with limited financial conditions, generic drugs are undoubtedly a burden-reducing option, but drug purchase channels must be formal to avoid the risk of counterfeit drugs. With the continuous launch of domestic and foreign generic drugs and intensified competition, the price of giritinib is expected to gradually decrease in the future. At the same time, the follow-up of domestic medical insurance policies may further improve patient accessibility and the affordability of long-term treatment.

Reference materials:https://www.drugs.com/